Coverage
Filings
| Filing | Date |
|---|---|
| Director/PDMR Shareholding | 5 Feb 2008 |
| Annual Report 2007 | 4 Feb 2008 |
| Director/PDMR Shareholding | 4 Feb 2008 |
| Director/PDMR Shareholding | 4 Feb 2008 |
| Final Results | 31 Jan 2008 |
| Research Update | 14 Jan 2008 |
| Treasury Stock | 3 Jan 2008 |
| Holding(s) in Company | 12 Dec 2007 |
| Research Update |
Novo Nordisk said Wednesday it plans to cut approximately 9,000 jobs globally as part of a major restructuring aimed at refocusing on its core diabetes and obesity drug businesses amid slowing growth.
Novo Nordisk said Friday its popular weight-loss drug Wegovy has been approved by the U.S. Food and Drug Administration to treat a common type of liver disease, further expanding the blockbuster drug's market.
Novo Nordisk said Thursday it will advance both injectable and oral versions of its experimental obesity drug, amycretin, into late-stage Phase 3 clinical trials.
| 11 Dec 2007 |
| Holding(s) in Company | 5 Dec 2007 |
| Formal Notice | 23 Nov 2007 |
| Research Update | 20 Nov 2007 |